Clinical Trials Browser

Rhabdomyosarcoma, Alveolar × Irinotecan × 90 days × Clear all

NCT02567435 2026-03-17

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

325 enrolled 14 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal